Myeloma Clinic Offers Multidisciplinary Approach, Expert Care
Multiple myeloma is a complex malignancy that can have far-reaching effects on patients including anemia, renal disease, lytic bone disease and osteoporosis that can lead to pathologic fractures, frequent infections and neuropathy. Given the
multi-organ impact of multiple myeloma, it is absolutely critical that physicians from different specialties come together to manage this disease. The multiple myeloma program at UNC achieves this goal by bringing physicians from medical oncology, bone marrow stem cell transplant, radiation oncology, orthopedic surgery, neurosurgery, interventional radiology and neurology together to help manage the many facets of this disease.
“The multiple myeloma program at UNC incorporates resources that we can bring to bear on every aspect of the disease,” says Peter Voorhees, MD, the clinic’s director.
The clinic treats multiple myeloma and other plasma cell-related disorders including solitary plasmacytoma, POEMS syndrome, AL amyloidosis, Waldenstrom Macroclobulinemia, MGUS, asymptomatic multiple myeloma and Castleman's disease.
New Clinical Trial Treating Hodgkin Lymphoma
UNC Lineberger, in collaboration with the Mayo Clinic and the UNC Cancer Network, is leading a clinical trial (LCCC1115) using brentuximab vedotin, an antibody-drug conjugate against CD30 antigen, for patients with stage I or stage II Hodgkin lymphoma. Brentuximab vedotin was recently approved by the FDA for relapsed Hodgkin lymphoma based on impressive response rates in heavily pretreated patients with Hodgkin lymphoma.
"The rationale for this trial is that brentuximab vedotin, when given as consolidation therapy, may safely replace radiation while preserving high cure rates in patients with early-stage Hodgkin lymphoma," explains Steven I. Park, MD, primary investigator on the study. "We believe this new treatment approach may change the standard of care for patients with newly diagnosed early-stage Hodgkin lymphoma."
More information is available at clinicaltrials.gov (NCT01578967).
Peter Voorhees, MD, is the director of the specialty clinic focused on multiple myeloma. View clinic's website.
Latest Clinical Trials Treating Multiple Myeloma
ACE-MM-101: A Phase 1, Open-Label, Multicenter Study of ACY-1215 in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
BMT-CTN-0702: A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
DFCI10-106: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009).
PRLX93936-0002: A Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Three Days a Week for Three Weeks Followed by a 9 Day Rest Period in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
PKB115125: A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma